Core Viewpoint - The company has entered into an exclusive sales agency agreement with Beijing Dekai Pharmaceutical Technology Co., Ltd. to promote and sell its anti-hair loss foam products in the mainland China market, aiming for collaborative growth and market expansion [1][2] Group 1: Agreement Details - The agreement involves the company's wholly-owned subsidiary, Kaixi Hong Kong, and focuses on the sales and marketing of the anti-hair loss foam agent in mainland China [1] - Both parties aim to leverage their respective strengths and resources to establish a close cooperative relationship, enhancing business development and product extension [1] Group 2: Product Advantages - The foam agent product offers superior transdermal penetration and higher scalp accumulation compared to tinctures, with a formulation that notably improves tolerability by being free of propylene glycol [1] - These advantages are expected to enhance overall user experience, positioning the foam agent as a preferred choice for daily hair loss prevention [1] Group 3: Market Strategy and Expectations - The collaboration is based on the complementary resources and strategic synergy between the two companies, aiming to maximize their strengths to jointly explore the market and achieve value creation [2] - The anti-hair loss foam product will access Dekai Pharmaceutical's extensive nationwide sales network, reaching over 25 million male chronic disease users and millions of active monthly users, significantly shortening the product's market introduction cycle [2] - The partnership is expected to enhance user trust and medication adherence through professional chronic disease management and education, leading to a substantial increase in sales and brand influence, with a target of exceeding 100 million RMB in sales [2]
开拓药业-B(09939)就防脱泡沫剂产品订立独家销售代理协议